Navigation
Open Access
Article
Development of recombinant allergens for diagnosis and therapy
Matthias Egger1,Michael Hauser1,Martin Himly1,Nicole Wopfner1,Michael Wallner1,Fatima Ferreira1
1
Christian Doppler Laboratory for Allergy Diagnosis and Therapy, Department of Molecular Biology, University of Salzburg, A-5020 Salzburg, Austria
DOI: 10.2741/E9 Volume 1 Issue 1, pp.77-90
Published: 01 June 2009
(This article belongs to the Special Issue New insights in diagnosis and treatment of allergic diseases)
Abstract

Allergic disease represents an increasing problem in industrialized countries. However, allergy diagnosis and specific immunotherapy, the only curative approach towards the treatment of IgE-mediated disorders, are still performed like in their very beginnings more than a century ago. The use of allergen extracts of undefined contents bears the risk of anaphylactic side effects and sensitization to new allergens during immunotherapy. This review focuses on production, physicochemical, and immunological requirements, as well as on the multiple advantages of recombinant allergens and hypoallergens in comparison to conventional allergen extracts used in allergy diagnosis and therapy. Recombinant allergens offer the perspective of molecule-based allergy diagnosis and consequently safe and patient-tailored immunotherapy.

Share and Cite
Matthias Egger, Michael Hauser, Martin Himly, Nicole Wopfner, Michael Wallner, Fatima Ferreira. Development of recombinant allergens for diagnosis and therapy. Frontiers in Bioscience-Elite. 2009. 1(1); 77-90.